Where is Pique Therapeutics's headquarters?
Pique Therapeutics's headquarters is located at 201 W. Main Street , Durham.
What is Pique Therapeutics's latest funding round?
Pique Therapeutics's latest funding round is Series B.
How much did Pique Therapeutics raise?
Pique Therapeutics raised a total of $1.39M.
Who are the investors of Pique Therapeutics?
Investors of Pique Therapeutics include Wilmington Investor Network, Piedmont Angel Network and Golden Pine Ventures.
Who are Pique Therapeutics's competitors?
Competitors of Pique Therapeutics include MaxCyte, Seattle Genetics, Cell Point, Stemline Therapeutics, ARIAD Pharmaceuticals, OxThera, Mirna Therapeutics, Immutep, Incline Therapeutics, Arcion Therapeutics and 21 more.
You May Also Like
Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Cell Point is a biotechnology company, develops radiodiagnostic imaging and intracellular therapeutic agents, and delivery systems for the administration of local regional radio/chemotherapy.
Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.
Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.
Incode BioPharmaceutics, Inc., has developed a product candidate, HC3-1496, that specifically targets the complement pathway. The mechanism-of-action of HC3-1496 results in enzymatic depletion of the complement protein C3, the key component for all three pathways of complement activation (alternative, classical, and mannose-lectin). The company's preclinical results show rapid depletion of C3 without any observed adverse events, including in primates. Importantly, HC3-1496 depletes C3 without the downstream activation of C5, thus preventing the formation of the C5a anaphylatoxin. A recent exciting result is the demonstration that HC3-1496 enhances the efficacy of an anti-CD20 mAb in a murine cancer model. These data will be presented at the upcoming American Society of Hematology (ASH) meeting in December. This clinical avenue is a high priority for InCode, and also underscores the increased appreciation for the role of complement in certain oncologic settings. The company have also demonstrated efficacy in several other animal models of human disease, including collagen-induced arthritis (RA), myocardial ischemia/reperfusion, and age related macular degeneration (AMD). The company have also demonstrated that HC3-1496 prevents the lysis of erythrocytes in patients with paroxysmal nocturnal hemoglobinuria (PNH). Given the emerging role of complement activation in the pathogenesis of grievous human disease, Incode intends to exploit the potent activity of HC3-1496. The company intend to initiate human clinical trials in selected indications within 18 months.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.